Literature DB >> 19187183

Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data.

M Christopher Roebuck1, Joshua N Liberman.   

Abstract

OBJECTIVE: To study the impact of various elements of pharmacy benefit design on both the absolute and relative utilization of generics, brands, retail pharmacy, and mail service. DATA SOURCE: Panel data on 1,074 plan sponsors covering 21.6 million individuals over 12 calendar quarters (2005-2007). STUDY
DESIGN: A retrospective analysis of pharmacy claims. STATISTICAL
METHODS: To control for potential endogeneity, linear fixed effects models were estimated for each of six dependent variables: the generic utilization rate, the brand utilization rate, the generic dispensing rate (GDR), the retail pharmacy utilization rate, the mail service utilization rate, and the mail distribution rate. PRINCIPAL
FINDINGS: Most member cost-share variables were nonlinearly associated with changes in prescription drug utilization. Marginal effects were generally greater in magnitude for brand out-of-pocket costs than for generic out-of-pocket costs. Time dummies, as well as other pharmacy benefit design elements, also yielded significant results.
CONCLUSIONS: Prior estimates of the effect of member cost sharing on prescription drug utilization may be biased if complex benefit designs, mail service fulfillment, and unmeasured factors such as pharmaceutical pipelines are not accounted for. Commonly cited relative utilization metrics, such as GDR, may be misleading if not examined alongside absolute prescription drug utilization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19187183      PMCID: PMC2699918          DOI: 10.1111/j.1475-6773.2008.00943.x

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  21 in total

1.  Effect of a three-tier prescription copay on pharmaceutical and other medical utilization.

Authors:  B Motheral; K A Fairman
Journal:  Med Care       Date:  2001-12       Impact factor: 2.983

2.  Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs.

Authors:  Kathleen A Fairman; Brenda R Motheral; Rochelle R Henderson
Journal:  Clin Ther       Date:  2003-12       Impact factor: 3.393

3.  Optimal health insurance for prevention and treatment.

Authors:  Randall P Ellis; Willard G Manning
Journal:  J Health Econ       Date:  2007-10-02       Impact factor: 3.883

4.  The demand for prescription drugs as a function of cost-sharing.

Authors:  A Leibowitz; W G Manning; J P Newhouse
Journal:  Soc Sci Med       Date:  1985       Impact factor: 4.634

5.  Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization.

Authors:  Pamela B Landsman; Winnie Yu; XiaoFeng Liu; Steven M Teutsch; Marc L Berger
Journal:  Am J Manag Care       Date:  2005-10       Impact factor: 2.229

6.  Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey.

Authors:  William H Shrank; Henry N Young; Susan L Ettner; Peter Glassman; Steven M Asch; Richard L Kravitz
Journal:  Am J Manag Care       Date:  2005-01       Impact factor: 2.229

7.  The effect of incentive-based formularies on prescription-drug utilization and spending.

Authors:  Haiden A Huskamp; Patricia A Deverka; Arnold M Epstein; Robert S Epstein; Kimberly A McGuigan; Richard G Frank
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

8.  Health insurance and the demand for medical care: evidence from a randomized experiment.

Authors:  W G Manning; J P Newhouse; N Duan; E B Keeler; A Leibowitz; M S Marquis
Journal:  Am Econ Rev       Date:  1987-06

9.  Pharmacy benefits and the use of drugs by the chronically ill.

Authors:  Dana P Goldman; Geoffrey F Joyce; Jose J Escarce; Jennifer E Pace; Matthew D Solomon; Marianne Laouri; Pamela B Landsman; Steven M Teutsch
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

10.  Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease.

Authors:  Kavita V Nair; Pamela Wolfe; Robert J Valuck; Marianne M McCollum; Julie M Ganther; Sonja J Lewis
Journal:  J Manag Care Pharm       Date:  2003 Mar-Apr
View more
  8 in total

1.  Pharma rebates, pharmacy benefit managers and employer outcomes.

Authors:  Ozden Gür Ali; Murali Mantrala
Journal:  Health Care Manag Sci       Date:  2010-05-28

2.  A comparison of drug formularies and the potential for cost-savings.

Authors:  Andrea L Kjos; Jon C Schommer; Yingli Yuan
Journal:  Am Health Drug Benefits       Date:  2010-09

Review 3.  Influencers of generic drug utilization: A systematic review.

Authors:  Jennifer N Howard; Ilene Harris; Gavriella Frank; Zippora Kiptanui; Jingjing Qian; Richard Hansen
Journal:  Res Social Adm Pharm       Date:  2017-08-04

4.  A Prescription for Drug Formulary Evaluation: An Application of Price Indexes.

Authors:  Jacob Glazer; Haiden A Huskamp; Thomas G McGuire
Journal:  Forum Health Econ Policy       Date:  2012-03-30

5.  Estimating the Effect of Health Insurance on Personal Prescription Drug Importation.

Authors:  Andrew R Zullo; Chanelle J Howe; Omar Galárraga
Journal:  Med Care Res Rev       Date:  2016-08-03       Impact factor: 3.929

6.  Factors Related to the Use of Topical vs. Oral NSAIDs for Sprains, Strains, and Contusions in a Senior Population: A Retrospective Analysis of Administrative Claims Data.

Authors:  Richard Sheer; Phil Schwab; Margaret Noyes Essex; Joseph C Cappelleri; Andrew Reiners; Joel Bobula; Margaret K Pasquale
Journal:  Drugs Aging       Date:  2018-10       Impact factor: 3.923

7.  Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.

Authors:  Matthias Stoll; Christian Kollan; Frank Bergmann; Johannes Bogner; Gerd Faetkenheuer; Carlos Fritzsche; Kirsten Hoeper; Heinz-August Horst; Jan van Lunzen; Andreas Plettenberg; Stefan Reuter; Jürgen Rockstroh; Hans-Jürgen Stellbrink; Osamah Hamouda; Barbara Bartmeyer
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

8.  Impact of Cost Sharing on Therapeutic Substitution: The Story of Statins in 2006.

Authors:  Pengxiang Li; J Sanford Schwartz; Jalpa A Doshi
Journal:  J Am Heart Assoc       Date:  2016-11-11       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.